These settings include (1) chronic viral infection, e.g., with HIV infection (as discussed above) and with parvovirus B19 infection21, (2) administration of therapeutic interferon, given for other indications16, and (3) a genetic disorder, e.g., the stimulator of interferon-gene (STING)-associated vasculopathy with onset in infancy (SAVI). This evidence concerns the gene STING1 and hereditary disease.